Delivery Order SPE2DB22D2103-SPE2DB25FR9KW
Award Date
6/24/25
Potential Completion Date
7/16/25
Potential Value
$3.2K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML medication. The contract has a ceiling value of $3,188.32 and a performance period ending on July 21, 2025. It is a firm-fixed-price contract with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the provision of XOLAIR 300 MG/2 ML AUTOINJECT 2ML medication. The contract has a ceiling value of $3,188.32 and a period of performance through July 3, 2025. It is a firm-fixed-price contract, without any set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
This is a federal contract award by the Defense Logistics Agency (DLA), a defense agency, to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a pharmaceutical product, with a firm fixed price ceiling value of $4,782.48 and a completion date of July 2, 2025. The contract is a delivery order and does not have a set-aside designation, indicating open competition....
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider based in Conshohocken, Pennsylvania. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a pharmaceutical product, with a ceiling value of $12,753.28. The contract is for a firm fixed price and has an ultimate completion date of July 1, 2025. Amerisourcebergen Drug Corp holds a significant...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a prescription medication, with a total ceiling value of $6,376.64 and an ultimate completion date of July 10, 2025. The contract is not set aside and is open to full and open competition. AmerisourceBergen Drug Corporation...
This is a $6,376.64 Firm Fixed Price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML medication, with a period of performance through July 17, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of Xolair 300 mg/2 ml autoinjectors. The contract has a ceiling value of $1,594.16 and a completion date of July 17, 2025. This award is not associated with a set-aside program. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XOLAIR 300 MG/2 ML SYRINGE 2ML, a pharmaceutical product, with a ceiling value of $17,321.90 and a performance period ending on July 8, 2025. The contract is a firm fixed-price delivery order, without any set-aside designation, indicating open competition....
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XOLAIR 300 MG/2 ML SYRINGE 2ML, a pharmaceutical product, with a ceiling value of $10,393.14. It is a firm fixed-price contract with a completion date of July 2, 2025. The contract is not set aside and is open to full and open competition. AmerisourceBergen Drug Corp holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,594.16 Firm Fixed Price delivery order is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a pharmaceutical product. The contract is not set aside and has a period of performance ending on July 14, 2025. Amerisourcebergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA...